Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Imlygic

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

    Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

    - PMLiVE

    LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

    Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

    - PMLiVE

    Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

    Almost one million new cases of gastric cancer are diagnosed globally every year

    - PMLiVE

    Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

    The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

    - PMLiVE

    Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials

    The candidate is currently under review for both interstitial lung diseases in the EU and US

    - PMLiVE

    Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

    The companies will focus on developing treatments for hard-to-treat ALT-positive tumours

    - PMLiVE

    Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

    The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

    - PMLiVE

    Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

    Immunoglobulin G4-related disease affects approximately 20,000 people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links